IS7915A - Ferli til að framleiða dúlóxetín og milliefni tilnotkunar í ferlinu - Google Patents

Ferli til að framleiða dúlóxetín og milliefni tilnotkunar í ferlinu

Info

Publication number
IS7915A
IS7915A IS7915A IS7915A IS7915A IS 7915 A IS7915 A IS 7915A IS 7915 A IS7915 A IS 7915A IS 7915 A IS7915 A IS 7915A IS 7915 A IS7915 A IS 7915A
Authority
IS
Iceland
Prior art keywords
acid addition
addition salt
duloxetine
doloxetine
intermediates
Prior art date
Application number
IS7915A
Other languages
English (en)
Inventor
Ramachandra Rao Dharmaraj
Narayanrao Kankan Rajendra
Original Assignee
Cipla Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd. filed Critical Cipla Ltd.
Publication of IS7915A publication Critical patent/IS7915A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IS7915A 2002-12-19 2005-06-24 Ferli til að framleiða dúlóxetín og milliefni tilnotkunar í ferlinu IS7915A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0229583.0A GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein
PCT/GB2003/005357 WO2004056795A1 (en) 2002-12-19 2003-12-10 A process for preparing duloxetine and intermediates for use therein

Publications (1)

Publication Number Publication Date
IS7915A true IS7915A (is) 2005-06-24

Family

ID=9949985

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7915A IS7915A (is) 2002-12-19 2005-06-24 Ferli til að framleiða dúlóxetín og milliefni tilnotkunar í ferlinu

Country Status (24)

Country Link
US (1) US7645890B2 (is)
EP (2) EP1690861B1 (is)
JP (1) JP5259048B2 (is)
KR (1) KR100926723B1 (is)
CN (2) CN100579975C (is)
AT (1) ATE353081T1 (is)
AU (2) AU2003292396B2 (is)
BR (1) BR0316902A (is)
CA (1) CA2510750A1 (is)
DE (1) DE60311599T2 (is)
ES (1) ES2279971T3 (is)
GB (1) GB0229583D0 (is)
HR (1) HRP20050657A2 (is)
IL (1) IL169232A (is)
IS (1) IS7915A (is)
MA (1) MA27706A1 (is)
MX (1) MXPA05006659A (is)
NZ (2) NZ540881A (is)
PL (1) PL377380A1 (is)
PT (1) PT1587801E (is)
RU (1) RU2351594C2 (is)
TN (1) TNSN05167A1 (is)
WO (1) WO2004056795A1 (is)
ZA (1) ZA200505656B (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027798A2 (en) * 2004-08-05 2006-03-16 Sun Pharmaceutical Industries Limited A process for preparation of an antidepressant compound
CZ297560B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
WO2006081515A2 (en) * 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs
MX2007010931A (es) * 2005-03-08 2007-10-16 Teva Pharma Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
EP1874754A1 (en) * 2005-03-14 2008-01-09 Teva Pharmaceutical Industries Ltd Pure duloxetine hydrochloride
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US7842717B2 (en) 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US7759500B2 (en) 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
CA2634007A1 (en) * 2005-12-12 2007-08-30 Medichem S.A. Improved synthesis and preparations of duloxetine salts
CZ299270B6 (cs) 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
WO2007077580A2 (en) * 2006-01-06 2007-07-12 Msn Laboratories Limited Improved process for pure duloxetine hydrochloride
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine
EP1976845A2 (en) * 2006-02-13 2008-10-08 Teva Pharmaceutical Industries Ltd A process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate
HU228458B1 (en) * 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
PT1857451E (pt) 2006-05-05 2010-10-25 Fidia Farmaceutici Processo para a preparação de uma substância intermédia útil para a síntese assimétrica da (+)duloxetina
CN101448815A (zh) * 2006-05-23 2009-06-03 特瓦制药工业有限公司 度洛西汀hci多晶型物
CN101484435A (zh) 2006-07-03 2009-07-15 兰贝克赛实验室有限公司 制备n-甲基-3-（1-萘氧基）-3-（2-噻吩基）丙胺及其纯对应异构体盐的方法
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
EP2114912B1 (en) 2006-12-22 2012-04-04 Synthon B.V. Process for making duloxetine and related compounds
HU227730B1 (en) 2006-12-22 2012-01-30 Richter Gedeon Nyrt Process for the preparation of duloxetine and for their the intermediates
EP2132192B1 (en) 2007-03-05 2013-04-24 Lupin Limited Novel process for preparation of duloxetine hydrochloride
WO2009019719A2 (en) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Process for the preparation of 3-aryloxy-3-arylpropanamines
WO2009130708A2 (en) * 2008-04-22 2009-10-29 Shodhana Laboratories Limited Preparation of duloxetine and its salts
WO2010025238A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
US8288141B2 (en) 2008-08-27 2012-10-16 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2011033366A2 (en) 2009-09-16 2011-03-24 Jubilant Life Sciences Limited Process for the preparation of duloxetine hydrochloride and its precursors
CN103360365A (zh) * 2012-04-06 2013-10-23 李晓红 一种抗抑郁症药物原料药盐酸度洛西汀的制备新工艺
CN104230882B (zh) * 2014-08-29 2017-03-08 宁波美诺华药业股份有限公司 一种度洛西汀盐酸盐杂质的制备方法
CN104829587B (zh) * 2015-05-08 2017-07-21 上海万巷制药有限公司 盐酸度洛西汀的制备
CN107382958B (zh) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 一种度洛西汀中间体的结晶方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH578532A5 (is) * 1971-08-03 1976-08-13 Cassella Farbwerke Mainkur Ag
PL233786A1 (is) 1980-11-14 1982-05-24 Lilly Co Eli
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
JPS62286959A (ja) * 1986-06-05 1987-12-12 Seitetsu Kagaku Co Ltd 光学活性シアノカルニチン塩の製造方法
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA2042346A1 (en) * 1990-05-17 1991-11-18 Michael Alexander Staszak Chiral synthesis of 1-aryl-3-aminopropan-1-ols
JPH09176157A (ja) * 1992-12-09 1997-07-08 Takeda Chem Ind Ltd 光学活性アミノクマラン誘導体
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US6162949A (en) 1994-12-16 2000-12-19 Uop Llc Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
US6458955B1 (en) 1994-12-16 2002-10-01 Uop Llc Process for preparation of pharmaceutically desired enantiomers
JP2002529499A (ja) 1998-11-13 2002-09-10 イーライ・リリー・アンド・カンパニー 痛みの治療方法
WO2000061540A1 (en) * 1999-04-09 2000-10-19 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
US6677485B2 (en) * 1999-12-17 2004-01-13 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
WO2003062219A1 (en) * 2002-01-24 2003-07-31 Eli Lilly And Company Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine

Also Published As

Publication number Publication date
ZA200505656B (en) 2006-04-26
GB0229583D0 (en) 2003-01-22
CN101125848B (zh) 2012-09-12
EP1690861B1 (en) 2012-09-12
RU2351594C2 (ru) 2009-04-10
PL377380A1 (pl) 2006-02-06
DE60311599T2 (de) 2007-10-25
US7645890B2 (en) 2010-01-12
PT1587801E (pt) 2007-04-30
ES2279971T3 (es) 2007-09-01
EP1690861A2 (en) 2006-08-16
HRP20050657A2 (en) 2005-10-31
EP1690861A3 (en) 2006-09-06
RU2005122662A (ru) 2006-01-20
ATE353081T1 (de) 2007-02-15
CA2510750A1 (en) 2004-07-08
JP5259048B2 (ja) 2013-08-07
AU2003292396B2 (en) 2010-05-20
AU2010200142A1 (en) 2010-02-04
EP1587801A1 (en) 2005-10-26
KR100926723B1 (ko) 2009-11-16
AU2003292396A1 (en) 2004-07-14
TNSN05167A1 (en) 2007-05-14
WO2004056795A1 (en) 2004-07-08
DE60311599D1 (de) 2007-03-22
EP1587801B1 (en) 2007-01-31
IL169232A (en) 2010-02-17
BR0316902A (pt) 2005-10-25
CN100579975C (zh) 2010-01-13
CN1747947A (zh) 2006-03-15
CN101125848A (zh) 2008-02-20
JP2006514030A (ja) 2006-04-27
AU2010200142B2 (en) 2012-04-12
MA27706A1 (fr) 2006-01-02
NZ540881A (en) 2008-09-26
KR20050089839A (ko) 2005-09-08
US20060205956A1 (en) 2006-09-14
MXPA05006659A (es) 2006-02-22
NZ569874A (en) 2009-11-27
WO2004056795A8 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
IS7915A (is) Ferli til að framleiða dúlóxetín og milliefni tilnotkunar í ferlinu
WO2006004100A8 (ja) １，２－ジヒドロピリジン－２－オン化合物の製造方法
PL1781683T3 (pl) Sposób wytwarzania 17-winylo-trifluorometanosulfonianów jako związków pośrednich
NZ598172A (en) Synthesis of boronic ester and acid compounds
TW200726754A (en) Chemical process
IL175024A0 (en) Method for producing 2-dihaloacyl-3-amino-acrylic acid esters and 3-dihalomethyl-pyrazole-4-carboxylic acid esters
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
CA2356188A1 (en) Method for the preparation of 5-cyanophthalide
MA29690B1 (fr) Procede de preparation de la 4beta-amino-4'-demethyl-4-desoxypodophyllotoxine
IS6435A (is) Aðferð til framleiðslu á sítalóprami
ATE517857T1 (de) Herstellung von 4-phenylbutansäure
ATE477227T1 (de) Verfahren zur herstellung eines trans-4-amino-1- cyclohexancarbonsäurederivats
BR0213814A (pt) Processos para a fabricação de 3-hidroxi-n, 1,6-trialquil-4-oxo-1, 4-diidro piridino-2-carboxamida
DE60102008D1 (de) Herstellungsverfahren für ein bekanntes terazolderivat
ATE266020T1 (de) Synthese von r-(+)-alpha-liponsäure
ZA200206443B (en) Method for the production of spirocyclic tetronic acid derivatives.
EA200600542A1 (ru) Способ для производства thip
ATE334972T1 (de) Verfahren für die herstellung von 4(5)-amino-5(4)-carboxamidoimidazolen und deren zwischenprodukte
EE05136B1 (et) Asendatud imidasopridiinhendite valmistamise meetod
NO20055991L (no) Fremgangsmate for syntetisering av heterocykliske forbindelser
GB0229688D0 (en) Solid-phase preparation of [18F] Fluorohaloalkanes
NO20055755L (no) Nytt intermediat for fremstillingen av terapeutisk aktive imidazopyridiner
HUP0003438A2 (hu) Eljárás 5-lipoxigenáz inhibitor hatású pirrol-karboxamid-származékok előállítására
EP1219610A4 (en) PROCESS FOR THE PREPARATION OF OXAZOLE DERIVATIVES
EP1566381A4 (en) PROCESS FOR PRODUCING 1- 2- (BENZIMIDAZOL-2-YL-THIO) ETHYL | PIPERAZINE OR SALTS THEREOF